We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

58 hedge funds and large institutions have $110M invested in Xenon Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

1.22% less ownership

Funds ownership: 70.37% → 69.15% (-1.2%)

2% less funds holding

Funds holding: 59 → 58 (-1)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

53% less capital invested

Capital invested by funds: $234M → $110M (-$124M)

Holders
58
Holders Change
-1
Holders Change %
-1.69%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
12
Increased
23
Reduced
6
Closed
12
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$5.54M
2
ACM
Aquilo Capital Management
California
+$3.19M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.89M
4
BlackRock
BlackRock
New York
+$2.52M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.61M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$11.8M
2
OM
Opaleye Management
Massachusetts
-$7.01M
3
FCMI
Foresite Capital Management IV
California
-$5.09M
4
JG
Jefferies Group
New York
-$4.3M
5
BC
Boxer Capital
California
-$3.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$828K +$1.17M +131,220 New
IPC
27
Invesco Private Capital
New York
$817K – – –
AS
28
Altshuler Shaham
Israel
$618K +$871K +98,007 New
Deutsche Bank
29
Deutsche Bank
Germany
$461K +$185K +20,777 +40%
SC
30
Scotia Capital
Ontario, Canada
$421K +$85.5K +9,618 +17%
AA
31
ALPS Advisors
Colorado
$365K +$514K +57,796 New
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$357K -$286K -32,146 -36%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$347K – – –
MCM
34
Moore Capital Management
New York
$316K +$311K +35,000 +233%
Two Sigma Advisers
35
Two Sigma Advisers
New York
$228K +$322K +36,200 New
BFM
36
Boothbay Fund Management
New York
$219K +$137K +15,407 +80%
Morgan Stanley
37
Morgan Stanley
New York
$219K +$231K +25,953 +298%
TI
38
Trexquant Investment
Connecticut
$194K +$174K +19,612 +175%
O
39
OppenheimerFunds
New York
$164K -$25.2K -2,836 -10%
NSEDCP
40
NJ State Employees Deferred Compensation Plan
New Jersey
$158K – – –
State Street
41
State Street
Massachusetts
$134K +$15.9K +1,788 +9%
EWM
42
Elmwood Wealth Management
California
$118K – – –
Geode Capital Management
43
Geode Capital Management
Massachusetts
$88K +$125K +14,084 New
Goldman Sachs
44
Goldman Sachs
New York
$80K +$113K +12,663 New
VF
45
Virtu Financial
New York
$80K +$113K +12,696 New
Northern Trust
46
Northern Trust
Illinois
$77K +$17.3K +1,948 +19%
Bank of Montreal
47
Bank of Montreal
Ontario, Canada
$74K – – –
Dimensional Fund Advisors
48
Dimensional Fund Advisors
Texas
$70K – – –
IVM
49
InterWest Venture Management
California
$52K – – –
CSS
50
Cubist Systematic Strategies
Connecticut
$41K +$57.6K +6,485 New
1
2
3

XENE Hedge Fund Activity: Q4 2018 in Review

58 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2018, worth a combined $110M — down 53% from $234M a quarter earlier.

Fund positioning in XENE was balanced in Q4 2018: 12 funds opened new positions, 12 closed out, 23 added to existing stakes and 6 trimmed.

The largest buyer was BVF Inc, adding an estimated $5.54M. The largest seller was Broadfin Capital, exiting entirely with an estimated $11.8M sold.

  • 58 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2018, down from 59 in Q3 2018.
  • Funds reported $110M of Xenon Pharmaceuticals stock for Q4 2018, down 53% quarter-over-quarter.
  • 12 funds opened new Xenon Pharmaceuticals positions in Q4 2018 and 12 closed out, a net change of 0 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2018 was BVF Inc, an estimated $5.54M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2018 was Broadfin Capital, an estimated $11.8M sold.

Based on aggregated 13F filings for Q4 2018.